59,673 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Voleon Capital Management LP

Voleon Capital Management LP acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 59,673 shares of the company’s stock, valued at approximately $624,000. Voleon Capital Management LP owned about 0.05% of Dyne Therapeutics at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of DYN. RA Capital Management L.P. boosted its holdings in Dyne Therapeutics by 52.2% in the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company’s stock worth $101,613,000 after buying an additional 3,333,248 shares during the last quarter. Braidwell LP boosted its holdings in Dyne Therapeutics by 431.6% in the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company’s stock worth $37,879,000 after buying an additional 2,940,162 shares during the last quarter. Armistice Capital LLC boosted its holdings in Dyne Therapeutics by 187.0% in the 1st quarter. Armistice Capital LLC now owns 2,768,000 shares of the company’s stock worth $28,953,000 after buying an additional 1,803,482 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Dyne Therapeutics in the 1st quarter worth about $18,828,000. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $15,097,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Guggenheim restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Stifel Nicolaus lowered their target price on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, July 31st. Robert W. Baird lowered their target price on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating on the stock in a report on Wednesday, June 18th. Chardan Capital lowered their target price on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. Finally, Jones Trading assumed coverage on Dyne Therapeutics in a report on Thursday, June 26th. They set a “buy” rating and a $30.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $34.07.

Dyne Therapeutics Stock Down 0.4%

DYN stock opened at $13.25 on Wednesday. The firm has a market cap of $1.88 billion, a PE ratio of -3.43 and a beta of 1.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. The firm’s 50 day moving average price is $10.96 and its 200-day moving average price is $11.13. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $37.08.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the sale, the chief executive officer owned 199,539 shares of the company’s stock, valued at approximately $2,675,817.99. The trade was a 1.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.